CJC-1295 vs Sermorelin: GHRH Analog Comparison

CJC-1295 vs Sermorelin: GHRH Analog Comparison

CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog available in two forms: with DAC (Drug Affinity Complex) providing an extended 8-day half-life for sustained GH elevation, and without DAC (mod-GRF 1-29) for pulsatile GH release. Sermorelin is the first 29 amino acids of natural GHRH, previously FDA-approved for pediatric growth hormone deficiency, with the most human clinical data among GHRH analogs. Both stimulate endogenous GH production through the GHRH receptor but differ significantly in half-life, dosing frequency, and GH release patterns.

Side-by-Side Comparison

Mechanism

GHRH receptor agonist (synthetic analog)

GHRH receptor agonist (natural GHRH 1-29)

Evidence Grade

B+

A-

Half-Life

~8 days (with DAC); ~30 min (no DAC)

~10-20 minutes

Route

Subcutaneous injection

Typical Dose

2 mg/week (DAC); 100 mcg 2-3x/day (no DAC)

200 - 300 mcg before bed daily

GH Release Pattern

Sustained elevation (DAC); pulsatile (no DAC)

Pulsatile (mimics natural secretion)

Dosing Frequency

2-3x/week (DAC); daily (no DAC)

Daily (typically before bed)

Best For

Sustained IGF-1 elevation, convenience

Natural GH pulsatility, clinical-grade research

FDA Status

Not FDA-approved; research compound

Previously FDA-approved (Geref); withdrawn 2008

Cost (research grade)

$$

$

CJC-1295: Pros & Cons

Advantages

Extended half-life (DAC) allows 2-3x/week dosing

Sustained GH and IGF-1 elevation

Strong synergy when combined with GHRP peptides

Mod-GRF 1-29 (no DAC) preserves pulsatile release

Well-tolerated in clinical studies

Considerations

DAC version may desensitize GH receptors over time

Less human clinical data than sermorelin

Sustained GH elevation (DAC) is non-physiological

Not FDA-approved in any formulation

Higher cost than sermorelin at research grade

Sermorelin: Pros & Cons

Previously FDA-approved with extensive human safety data

Natural pulsatile GH release pattern

Available through compounding pharmacies

Lowest cost GHRH analog

Best-characterized pharmacokinetics in humans

Preserves hypothalamic-pituitary feedback

Very short half-life requires daily injection

Weaker GH pulse amplitude than CJC-1295 (no DAC)

Requires consistent bedtime dosing for optimal results

Some users develop antibodies with long-term use

Withdrawn from market (commercial, not safety reasons)

Which Is Right for Your Research?

Decision Guide

Choose CJC-1295 with DAC if: Your research prioritizes convenience and sustained GH/IGF-1 elevation. The 8-day half-life allows infrequent dosing and provides steady-state GH levels. Best suited for protocols where consistent anabolic signaling is more important than preserving natural pulsatile secretion.

Choose CJC-1295 without DAC (mod-GRF 1-29) if: You want stronger GH pulse amplitude than sermorelin while maintaining pulsatile release. Often paired with a GHRP (like ipamorelin) for synergistic GH secretion. This is the most popular research GHRH analog for combined protocols.

Choose sermorelin if: You prioritize the deepest human safety data, natural physiological GH pulsatility, and the lowest cost. Sermorelin's FDA history and compounding pharmacy availability make it the most accessible and well-characterized GHRH analog for clinical research.

Frequently Asked Questions

CJC-1295 with DAC produces more sustained GH elevation due to its 8-day half-life. Sermorelin mimics natural pulsatile GH release better. CJC-1295 without DAC (mod-GRF 1-29) provides stronger GH pulses than sermorelin while maintaining pulsatility. The choice depends on whether sustained or pulsatile GH release is desired for your research.

CJC-1295 with DAC binds to albumin, extending half-life to ~8 days with sustained, non-pulsatile GH elevation. Without DAC (mod-GRF 1-29) has a 30-minute half-life producing discrete GH pulses. The DAC version requires less frequent dosing but may desensitize receptors, while the non-DAC version preserves natural pulsatile patterns.

Yes, sermorelin (Geref) was FDA-approved in 1997 for diagnostic use and pediatric GH deficiency treatment. It was voluntarily withdrawn in 2008 for commercial reasons, not safety concerns. It remains available as a compounded peptide and has the most human clinical data of any GHRH analog.

Related Protocol Guides

Compare More

Verified Research Suppliers

★ LiveWell Peptides — Preferred Vendor • cGMP Certified Preferred vendor

Core Peptides — Third-party tested

— Broad catalog

Biotech Peptides — USA-based

Related Tools & Resources

Related Resources